Search This Blog

Monday, January 14, 2019

FDA approves expanded use of Sanofi’s Adacel vaccine


The Food and Drug Administration has approved the expanded use of Adacel to include repeat vaccination to help protect against tetanus, diphtheria and pertussis. It is now the first and only Tdap vaccine in the U.S. approved for a repeat dose in people 10 through 64 years of age 8 years or more after the first vaccination. Adacel is also the only Tdap vaccine available in a syringe made without natural rubber latex, which may help reduce risk to patients with an allergy.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.